United Therapeutics (UTHR) Wells Fargo 21st Annual Healthcare Conference summary

Strategic product pipeline and growth outlook

• Fourteen new products are being rolled out over the next few years, targeting a cumulative annual pharma revenue of $50–100 billion, with multiple launches planned each year.

• Key near-term events include NDA submissions and PDUFA dates for nebulized Tyvaso in IPF and Gen RAL-DPI for pulmonary hypertension, with the latter expected to receive FDA approval by June next year.

• The addressable patient population across PH-COPD, pulmonary fibrosis, and pulmonary hypertension is estimated at one million, with a projected 50% capture rate.

• Accelerated share repurchase of $500 million brings total recent repurchases to $4 billion, reflecting confidence in future growth and undervaluation relative to market cap.

• Strong intellectual property protection extends into the 2040s, supporting long-term exclusivity for key products.

Product innovation and market strategy

• Gen RAL-DPI is positioned as the only product to show clinical improvement in PH, with a once-daily pill format expected to shift prescribing patterns.

• Triple Gen RAL-DPI, combining three mechanisms of action in one pill, is expected to capture over 80% of PH patients by decade's end, with regulatory filings planned within 12–24 months after Gen RAL-DPI approval.

• The soft mist inhaler (Tresmi) for treprostinil is anticipated to drive growth in the inhalable franchise, with plans for rapid expansion into ILD, IPF, and PPF markets.

• The company follows an "approve and then improve" algorithm, sequentially advancing products through regulatory pathways and device innovations.

• Significant investments in manufacturing capacity, including a new 50,000-patient annual production facility for RAL-DPI, support anticipated demand.

Commercial opportunity and financial discipline

• For IPF, a $100 million investment was made to prepare 10,000 patient starter kits for launch, aiming to capture 10% of the 100,000–150,000 US patient population in the first year.

• Rapid enrollment in the PPF trial exceeded expectations, driven by strong physician interest and promising early results.

• Separate clinical trials for IPF and PPF ensure on-label use and reimbursement, with digital AI models and prior trial data supporting high confidence in outcomes.

• Revenue guidance is set at $4 billion as a near-term step, with expectations for rapid growth as new products launch and gain traction.

• Operating budgets will increase to 55% of prior year revenue to support expansion, while maintaining financial discipline and avoiding unnecessary business development.